194 related articles for article (PubMed ID: 33773907)
1. Rebound increases in chemokines by CXCR2 antagonist in breast cancer can be prevented by PKCδ and PKCε activators.
Erin N; Tavşan E; Akdeniz Ö; Isca VMS; Rijo P
Cytokine; 2021 Jun; 142():155498. PubMed ID: 33773907
[TBL] [Abstract][Full Text] [Related]
2. Autocrine control of MIP-2 secretion from metastatic breast cancer cells is mediated by CXCR2: a mechanism for possible resistance to CXCR2 antagonists.
Erin N; Nizam E; Tanrıöver G; Köksoy S
Breast Cancer Res Treat; 2015 Feb; 150(1):57-69. PubMed ID: 25682075
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte signaling through CXC chemokine receptor-2 is detrimental to liver recovery after ischemia/reperfusion in mice.
Kuboki S; Shin T; Huber N; Eismann T; Galloway E; Schuster R; Blanchard J; Edwards MJ; Lentsch AB
Hepatology; 2008 Oct; 48(4):1213-23. PubMed ID: 18688883
[TBL] [Abstract][Full Text] [Related]
4. The CXCR2/CXCL2 signalling pathway - An alternative therapeutic approach in high-grade glioma.
Acker G; Zollfrank J; Jelgersma C; Nieminen-Kelhä M; Kremenetskaia I; Mueller S; Ghori A; Vajkoczy P; Brandenburg S
Eur J Cancer; 2020 Feb; 126():106-115. PubMed ID: 31927212
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil recruitment by chemokines Cxcl1/KC and Cxcl2/MIP2: Role of Cxcr2 activation and glycosaminoglycan interactions.
Sawant KV; Sepuru KM; Lowry E; Penaranda B; Frevert CW; Garofalo RP; Rajarathnam K
J Leukoc Biol; 2021 Apr; 109(4):777-791. PubMed ID: 32881070
[TBL] [Abstract][Full Text] [Related]
6. Epithelial-stromal communication via CXCL1-CXCR2 interaction stimulates growth of ovarian cancer cells through p38 activation.
Park GY; Pathak HB; Godwin AK; Kwon Y
Cell Oncol (Dordr); 2021 Feb; 44(1):77-92. PubMed ID: 32910411
[TBL] [Abstract][Full Text] [Related]
7. A synthetic, non-peptide CXCR2 antagonist blocks MIP-2-induced neutrophil migration in mice.
Matzer SP; Zombou J; Sarau HM; Röllinghoff M; Beuscher HU
Immunobiology; 2004; 209(3):225-33. PubMed ID: 15518334
[TBL] [Abstract][Full Text] [Related]
8. Programmed Cell Death 10 Mediated CXCL2-CXCR2 Signaling in Regulating Tumor-Associated Microglia/Macrophages Recruitment in Glioblastoma.
Zhang Q; Wang J; Yao X; Wu S; Tian W; Gan C; Wan X; You C; Hu F; Zhang S; Zhang H; Zhao K; Shu K; Lei T
Front Immunol; 2021; 12():637053. PubMed ID: 34108959
[TBL] [Abstract][Full Text] [Related]
9. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P.
Nizam E; Erin N
Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097
[TBL] [Abstract][Full Text] [Related]
10. Cell-specific regulatory effects of CXCR2 on cholestatic liver injury.
Konishi T; Schuster RM; Goetzman HS; Caldwell CC; Lentsch AB
Am J Physiol Gastrointest Liver Physiol; 2019 Dec; 317(6):G773-G783. PubMed ID: 31604030
[TBL] [Abstract][Full Text] [Related]
11. Cross-desensitization among CXCR1, CXCR2, and CCR5: role of protein kinase C-epsilon.
Nasser MW; Marjoram RJ; Brown SL; Richardson RM
J Immunol; 2005 Jun; 174(11):6927-33. PubMed ID: 15905535
[TBL] [Abstract][Full Text] [Related]
12. Developmental expression of two CXC chemokines, MIP-2 and KC, and their receptors.
Luan J; Furuta Y; Du J; Richmond A
Cytokine; 2001 Jun; 14(5):253-63. PubMed ID: 11444905
[TBL] [Abstract][Full Text] [Related]
13. CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer.
Zhang H; Ye YL; Li MX; Ye SB; Huang WR; Cai TT; He J; Peng JY; Duan TH; Cui J; Zhang XS; Zhou FJ; Wang RF; Li J
Oncogene; 2017 Apr; 36(15):2095-2104. PubMed ID: 27721403
[TBL] [Abstract][Full Text] [Related]
14. Activation of CXCL5-CXCR2 axis promotes proliferation and accelerates G1 to S phase transition of papillary thyroid carcinoma cells and activates JNK and p38 pathways.
Cui D; Zhao Y; Xu J
Cancer Biol Ther; 2019; 20(5):608-616. PubMed ID: 30404567
[TBL] [Abstract][Full Text] [Related]
15. A crucial role for TNF-alpha in mediating neutrophil influx induced by endogenously generated or exogenous chemokines, KC/CXCL1 and LIX/CXCL5.
Vieira SM; Lemos HP; Grespan R; Napimoga MH; Dal-Secco D; Freitas A; Cunha TM; Verri WA; Souza-Junior DA; Jamur MC; Fernandes KS; Oliver C; Silva JS; Teixeira MM; Cunha FQ
Br J Pharmacol; 2009 Oct; 158(3):779-89. PubMed ID: 19702783
[TBL] [Abstract][Full Text] [Related]
16. Long chain n-3 polyunsaturated fatty acids increase the efficacy of docetaxel in mammary cancer cells by downregulating Akt and PKCε/δ-induced ERK pathways.
Chauvin L; Goupille C; Blanc C; Pinault M; Domingo I; Guimaraes C; Bougnoux P; Chevalier S; Mahéo K
Biochim Biophys Acta; 2016 Apr; 1861(4):380-90. PubMed ID: 26821209
[TBL] [Abstract][Full Text] [Related]
17. CXCL2-CXCR2 axis mediates αV integrin-dependent peritoneal metastasis of colon cancer cells.
Lepsenyi M; Algethami N; Al-Haidari AA; Algaber A; Syk I; Rahman M; Thorlacius H
Clin Exp Metastasis; 2021 Aug; 38(4):401-410. PubMed ID: 34115261
[TBL] [Abstract][Full Text] [Related]
18. CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells.
Kim JH; Lee SJ; Kang KW; Lee BH; Park Y; Kim BS
Biochem Pharmacol; 2021 Aug; 190():114658. PubMed ID: 34146540
[TBL] [Abstract][Full Text] [Related]
19. CXCR2 antagonists block the N-Ac-PGP-induced neutrophil influx in the airways of mice, but not the production of the chemokine CXCL1.
Braber S; Overbeek SA; Koelink PJ; Henricks PA; Zaman GJ; Garssen J; Kraneveld AD; Folkerts G
Eur J Pharmacol; 2011 Oct; 668(3):443-9. PubMed ID: 21458445
[TBL] [Abstract][Full Text] [Related]
20. Role of PKC-delta on substance P-induced chemokine synthesis in pancreatic acinar cells.
Ramnath RD; Sun J; Adhikari S; Zhi L; Bhatia M
Am J Physiol Cell Physiol; 2008 Mar; 294(3):C683-92. PubMed ID: 18160487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
